Screener
Cytokinetics CYTK Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' deficit | ||
| Preferred stock | — | — |
| Common stock | 138 | 123 |
| Additional paid-in capital | 3,721,713 | 2,826,341 |
| Accumulated other comprehensive (loss) income | (3,826) | 630 |
| Accumulated deficit | (3,891,512) | (3,486,719) |
| Total stockholders' deficit | (173,487) | (659,625) |
| Total liabilities and stockholders' deficit | $1,924,551 | $1,424,537 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's total liabilities & equity?
- Cytokinetics (CYTK) reported total liabilities & equity of $1.92B in Q2 2026.
- How has Cytokinetics's total liabilities & equity changed year-over-year?
- Cytokinetics's total liabilities & equity increased by 57.0% year-over-year, from $1.23B to $1.92B.
- What is the long-term trend for Cytokinetics's total liabilities & equity?
- Over 5 years (2020 to 2025), Cytokinetics's total liabilities & equity has grown at a 21.7% compound annual growth rate (CAGR), from $533.8M to $1.42B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Cytokinetics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude